戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e the bias of particular mutations caused by favipiravir.
2  treated with a combination of ribavirin and favipiravir.
3   The mutant viruses remained susceptible to favipiravir.
4 reatment of monoclonal antibodies (ZMAb) and favipiravir.
5 ing a centralised online process to receive: favipiravir (1,800 mg twice daily on Day 1 followed by 4
6                                In US317 (526 favipiravir, 169 placebo), favipiravir did not significa
7 complicated influenza who were randomized to favipiravir (1800 mg twice a day on day 1, 800 mg twice
8 ipants were randomized to receive placebo or favipiravir (1800 mg twice daily [BID] day 1, 800 mg BID
9 s and fever of <=48 hours were randomized to favipiravir (1800 mg twice daily [BID] on day 1, 800 mg
10                                In US316 (301 favipiravir, 322 placebo), favipiravir was associated wi
11  in Hartley guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leadin
12                               In the case of favipiravir, a polymerase inhibitor with activity agains
13 d trial, in which all patients would receive favipiravir along with standardized care.
14                                              Favipiravir, an antiviral developed for the treatment of
15                                              Favipiravir, an oral, RNA-dependent RNA polymerase inhib
16 meric 3-hydroxypyrazine/3-pyrazinone pair of favipiravir and its 6-substituted analogues, 6-Cl, 6-Br,
17 There was no significant interaction between favipiravir and lopinavir-ritonavir (interaction coeffic
18  in testing whether viruses are resistant to favipiravir and may help demonstrate the effect of favip
19   We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased surv
20 s infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficit
21                     For all compounds except favipiravir and TFM, the fastest degradation was observe
22                 The pharmacokinetics of oral favipiravir and the relationships of plasma concentratio
23                             A combination of favipiravir and zanamivir successfully cleared influenza
24  left untreated or treated with ribavirin or favipiravir, and we put the results in perspective with
25 ws no antagonistic effect when combined with favipiravir, another broadly acting antiviral nucleoside
26          Measurement of the tissue uptake of favipiravir as determined by PET may be a more important
27                      Our data do not support favipiravir at commonly used doses in outpatients with u
28 to better understand the antiviral effect of favipiravir by developping the first mathematical model
29 ipeline to show that the mutagenic effect of favipiravir can be measured by whole-genome sequencing o
30                   These results suggest that favipiravir can induce norovirus mutagenesis in vivo, wh
31                          We demonstrate that favipiravir causes mutations and show that favipiravir p
32 eration sequencing (NGS) to demonstrate that favipiravir causes mutations in influenza RNA.
33  Wide interindividual variability existed in favipiravir concentrations, and this regimen failed to r
34 inistration was associated with lower plasma favipiravir concentrations.
35 her mean ratios of the metabolite T-705M1 to favipiravir, consistent with greater metabolism, and wer
36 lphenol (TFM), florasulam, voriconazole, and favipiravir, covering key fluorine motifs (benzylic-CF(3
37               All participants received oral favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d
38                     Moreover, a high dose of favipiravir decreased virus transmission by direct conta
39                In contrast, the results with favipiravir demonstrate that an antiviral drug at nontox
40 roviding a proof-of-principle for the use of favipiravir derivatives or mutagenic nucleosides in the
41 sease progression, early treatment with oral favipiravir did not prevent their disease progression fr
42     In US317 (526 favipiravir, 169 placebo), favipiravir did not significantly reduce time to allevia
43 er research is needed to ascertain if higher favipiravir doses are effective and safe for patients wi
44 okinetics in humans, our model predicts that favipiravir doses larger than 1200 mg twice a day should
45                                         This favipiravir dosing regimen demonstrated significant anti
46                                              Favipiravir drug levels were lower in the combination ar
47                          Our model estimates favipiravir EC50 in vivo to 2.89 ug.mL-1, which is much
48 fficacy, and factors associated with reduced favipiravir exposure.
49 upport the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.
50 zation to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients.
51 ion, application of PET to the evaluation of favipiravir has demonstrated the importance of dosing re
52                         One of these, T-705 (favipiravir), has a mechanism of action that is not full
53 s assessing the efficacy and tolerability of favipiravir in acute influenza.
54 d, randomized controlled outpatient trial of favipiravir in asymptomatic or mildly symptomatic adults
55                                  The role of favipiravir in preventing disease progression in coronav
56 lect data on the safety and effectiveness of favipiravir in reducing mortality and viral load in pati
57 nfection, demonstrating the effectiveness of favipiravir in this case.
58 ules to accurately and quantitatively detect favipiravir-induced mutations and to sample orders of ma
59  mutagen, but the precise mutation bias that favipiravir induces in influenza virus RNAs has not been
60 igh-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A
61                                              Favipiravir is a broad-spectrum antiviral drug that may
62                                              Favipiravir is a broad-spectrum antiviral which is effec
63  a standard diagnostic pipeline to show that favipiravir is acting on the virus by revealing the muta
64                        Despite limited data, favipiravir is administered to patients with coronavirus
65                                              Favipiravir is an important selective antiviral against
66                                              Favipiravir is cleared through the kidney as previously
67                 The RNA polymerase inhibitor favipiravir is currently in clinical trials as a treatme
68                                              Favipiravir is routinely used in many countries, but eff
69                    This will be important if favipiravir is used during a future influenza pandemic.
70  on perceived potency and clinical efficacy, favipiravir is widely used to treat COVID-19.
71                                       Higher favipiravir levels with average Cmin>20 ug/mL were assoc
72        Previous research has identified that favipiravir likely acts as a mutagen, but the precise mu
73                                      For the favipiravir+lopinavir-ritonavir, favipiravir+placebo, lo
74           We aimed to evaluate the effect of favipiravir, lopinavir-ritonavir or the combination of b
75 ate certainty) and systemic corticosteroids, favipiravir, molnupiravir, and umifenovir probably also
76 s were lower in the combination arm than the favipiravir monotherapy arm, possibly due to poor absorp
77                       They also suggest that favipiravir monotherapy merits further study in patients
78 ravir and may help demonstrate the effect of favipiravir on viruses in a clinical setting.
79 S-CoV-2-infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin
80 -to-moderate COVID-19 were 1:1 randomized to favipiravir or placebo.
81 -ritonavir placebo, lopinavir-ritonavir plus favipiravir placebo, or both placebos.
82 pants had undetectable virus at Day 5 in the favipiravir+placebo arm compared to placebo only (46.3%
83 primary analysis, the mean viral load in the favipiravir+placebo arm had changed by -0.57 log10 (95%
84     For the favipiravir+lopinavir-ritonavir, favipiravir+placebo, lopinavir-ritonavir+placebo, and pl
85  200 mg/50 mg 4 times daily on Days 2 to 7), favipiravir plus lopinavir-ritonavir placebo, lopinavir-
86 o hypoxia occurred in 46 (18.4%) patients on favipiravir plus standard care and 37 (14.8%) on standar
87              Patients were randomized 1:1 to favipiravir plus standard care or standard care alone.
88                     We demonstrate here that Favipiravir predominantly exerts an antiviral effect thr
89 t favipiravir causes mutations and show that favipiravir primarily acts as a guanine analogue and sec
90 lness alleviation compared to placebo and to favipiravir recipients with lower average Cmin values in
91 ow that the broad-range antiviral nucleoside favipiravir reduces viral load in vivo by exerting antiv
92                                              Favipiravir remained highly effective against lethal LAS
93                                              Favipiravir requires further evaluation with considerati
94              Here we report the structure of favipiravir ribonucleoside triphosphate (favipiravir-RTP
95 ls an unusual, nonproductive binding mode of favipiravir-RTP at the catalytic site of SARS-CoV-2 RdRp
96  of favipiravir ribonucleoside triphosphate (favipiravir-RTP) in complex with the SARS-CoV-2 RNA-depe
97 CoV-2 amplicon-based sequencing, we assessed favipiravir's impact on mutagenesis.
98            Recently, the nucleotide analogue favipiravir showed a high antiviral efficacy, with 100%
99                       However, high doses of favipiravir significantly reduced infectious virus titer
100     In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue
101                                              Favipiravir suppressed Lassa virus replication in cell c
102      We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in c
103                            Susceptibility to favipiravir (T-705) was assessed using plaque reduction
104                                              Favipiravir (T705; 6-fluoro-3-hydroxypyrazine-2-carboxam
105                                       [(18)F]favipiravir tissue uptake and distribution was similar i
106 revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of tr
107 e events were observed in 13.8% and 14.8% of favipiravir-treated and placebo-treated subjects, respec
108 ysis indicated a longer survival time in the favipiravir-treated group (P = .015).
109                    The case-fatality rate in favipiravir-treated patients was lower than in untreated
110  Uric acid elevation was more frequent among favipiravir-treated subjects (19.9% vs 2.8%).
111 e associated with survival (P < .001), while favipiravir treatment showed no statistically significan
112                                              Favipiravir treatment was offered to patients with EVD o
113 rs, alterations in blood chemistry findings, favipiravir treatment, and outcome.
114 TAT2 knockout (KO) hamsters is responsive to favipiravir treatment, which protected all animals from
115                      Fluorine-18 labeling of favipiravir was achieved in a one-pot, two-step synthesi
116                                              Favipiravir was administered at 1800 mg 2x/day on day 1
117 ribution in mice naive to and pre-dosed with favipiravir was assessed by PET and gamma counting of ti
118     In US316 (301 favipiravir, 322 placebo), favipiravir was associated with a 14.4-hour reduction (m
119                               In both trials favipiravir was associated with reduced viral titers, RN
120 rent study, a method for synthesis of [(18)F]favipiravir was developed and the biodistribution in mic
121                                         Oral favipiravir was part of the current standard of care in
122              The main mechanism of action of favipiravir was to decrease virus infectivity, with an e
123                                              Favipiravir was well tolerated but lacked efficacy in TT
124                                              Favipiravir was well tolerated.
125 nificantly different between adults starting favipiravir within <72 h of symptoms compared to others.
126                   The exact mechanism of how favipiravir works to inhibit influenza is still unclear.

 
Page Top